London startup, Koalaa, whose world-first soft prosthetic arms are aiding independence for individuals with limb differences around the world, has closed a funding round of $1.2 million (£925,000).  The round was initiated by existing investor British Design Fund and includes £200,000 secured from the Imperial College Enterprise Fund II (ICEF), which invests in startup companies that have a strong connection to the University.  Business angels also took part in the round. The funds raised in this round, which started in July 2022, are being used to expand Koalaa’s business internationally.

PulmoBioMed  - a Northumbria University spin-out which has developed a new lung test that could lead to earlier diagnosis of asthma and other conditions - has raised £1.4m to help commercialise its technology and target the US market.  The investment round was led by the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures, and included Northumbria University, SFC Capital and private investors in the USA, EU and UK. The company has also secured a £700,000 grant from Innovate UK to help it demonstrate the benefits of its technology.

Newly launched TCR company ALKemist Bio has closed a €6.9 million funding round to develop first-in-class TCR Cell Therapy for ALK-Positive Tumors.

Mesenbio, a University of York spin-out that is developing a novel treatment for arthritis created from engineered human stem cells, has raised £1.4m in an investment round co-led by DSW Ventures and NG Bio alongside grant funding from Innovate UK.

The treatment will initially target rheumatoid arthritis, an autoimmune disease that impacts nearly half a million adults and children in the UK alone, causing debilitating joint pain and inflammation of the hands, knees, elbows, ankles, and wrists.

SFC Capital and the University of Birmingham's Precision Health Technologies Accelerator (PHTA) have agreed a landmark investment partnership to support promising HealthTech and MedTech companies.

Sussex-based angel investment group South East Angels has announced its recent investment in Siloton - a startup on a mission to leverage the latest advancements in integrated photonics to improve the global population’s health.  Looking to serve the 25% of over 60’s with age-related macular degeneration, Siloton has developed an at-home diagnostic imaging device that reduces the burden of treatment, alleviating pressure on healthcare systems, while helping patients retain their sight for longer.

1nhaler, a Scotland-based drug delivery device developer, has raised £2 million to develop its unique single-use dry powder inhaler (DPI), led by Archangels.

Inhalable medicines are already widely used to treat conditions such as asthma, epilepsy, allergies and Parkinson’s but, to date, delivery options have been limited due to user accessibility, cost, performance and impact on the environment. 1nhaler has developed a way of enabling many different dry powder drugs to be readily delivered in a sustainable, low-cost delivery device.

Renovos Biologics, a biotechnology company that is developing a proprietary nanoclay gel carrier system to precisely deliver therapeutic agents for regenerative medicine, has received investment from five Henley Business Angels members, contributing towards a funding round, which together with non-dilutive grants, amounts to £2.3 million.

Biotech start up Mitra Bio has been named the winner of South East Angels' hosted London Startup Roadshow.

SAN DIEGO, USA: Digital health company has CARI Health formed an Advisory Board to support development of its wearable remote medication monitoring device.

DN Capital, the leading European early-stage venture capital firm, and health-tech VC, YZR Capital has led a €5.1m Seed round for filu, a German startup that builds modern tech-enabled veterinary clinics. Lukas Keindl, co-founder of US-based Bond Vet, Rivus Ventures, Auxxo Female Catalyst Fund and angel investors also participated in the round.

San Diego, USA: Digital health startup CARI Health has been awarded an SBIR Fast Track grant from the National Institute on Drug Abuse (NIDA), an agency of the National Institutes of Health (NIH), to help it bring the world’s first wearable medication monitor to market. CARI Health is eligible for up to $2.8M over three years as project milestones are successfully completed within Phase I and Phase II portions of the grant. The award funding will go toward supporting product development and conducting human clinical studies for CARI Health’s wearable remote medication monitoring device.